BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 20333681)

  • 1. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers.
    Hayami S; Kelly JD; Cho HS; Yoshimatsu M; Unoki M; Tsunoda T; Field HI; Neal DE; Yamaue H; Ponder BA; Nakamura Y; Hamamoto R
    Int J Cancer; 2011 Feb; 128(3):574-86. PubMed ID: 20333681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia.
    Schenk T; Chen WC; Göllner S; Howell L; Jin L; Hebestreit K; Klein HU; Popescu AC; Burnett A; Mills K; Casero RA; Marton L; Woster P; Minden MD; Dugas M; Wang JC; Dick JE; Müller-Tidow C; Petrie K; Zelent A
    Nat Med; 2012 Mar; 18(4):605-11. PubMed ID: 22406747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LSD1 inhibition: a therapeutic strategy in cancer?
    Lynch JT; Harris WJ; Somervaille TC
    Expert Opin Ther Targets; 2012 Dec; 16(12):1239-49. PubMed ID: 22957941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells.
    Fiskus W; Sharma S; Shah B; Portier BP; Devaraj SG; Liu K; Iyer SP; Bearss D; Bhalla KN
    Leukemia; 2014 Nov; 28(11):2155-64. PubMed ID: 24699304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LSD1 overexpression is associated with poor prognosis in basal-like breast cancer, and sensitivity to PARP inhibition.
    Nagasawa S; Sedukhina AS; Nakagawa Y; Maeda I; Kubota M; Ohnuma S; Tsugawa K; Ohta T; Roche-Molina M; Bernal JA; Narváez AJ; Jeyasekharan AD; Sato K
    PLoS One; 2015; 10(2):e0118002. PubMed ID: 25679396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pluripotent stem cell protein Sox2 confers sensitivity to LSD1 inhibition in cancer cells.
    Zhang X; Lu F; Wang J; Yin F; Xu Z; Qi D; Wu X; Cao Y; Liang W; Liu Y; Sun H; Ye T; Zhang H
    Cell Rep; 2013 Oct; 5(2):445-57. PubMed ID: 24139802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells.
    Harris WJ; Huang X; Lynch JT; Spencer GJ; Hitchin JR; Li Y; Ciceri F; Blaser JG; Greystoke BF; Jordan AM; Miller CJ; Ogilvie DJ; Somervaille TC
    Cancer Cell; 2012 Apr; 21(4):473-87. PubMed ID: 22464800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysine-specific histone demethylase 1 (LSD1): A potential molecular target for tumor therapy.
    Chen Y; Jie W; Yan W; Zhou K; Xiao Y
    Crit Rev Eukaryot Gene Expr; 2012; 22(1):53-9. PubMed ID: 22339659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversible inhibitors of LSD1 as therapeutic agents in acute myeloid leukemia: clinical significance and progress to date.
    Mould DP; McGonagle AE; Wiseman DH; Williams EL; Jordan AM
    Med Res Rev; 2015 May; 35(3):586-618. PubMed ID: 25418875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of LSD1 (lysine-specific demethylase 1) suppresses growth and alters gene expression of human colon cancer cells in a p53- and DNMT1(DNA methyltransferase 1)-independent manner.
    Jin L; Hanigan CL; Wu Y; Wang W; Park BH; Woster PM; Casero RA
    Biochem J; 2013 Jan; 449(2):459-68. PubMed ID: 23072722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer.
    Lv T; Yuan D; Miao X; Lv Y; Zhan P; Shen X; Song Y
    PLoS One; 2012; 7(4):e35065. PubMed ID: 22493729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.
    Mohammad HP; Smitheman KN; Kamat CD; Soong D; Federowicz KE; Van Aller GS; Schneck JL; Carson JD; Liu Y; Butticello M; Bonnette WG; Gorman SA; Degenhardt Y; Bai Y; McCabe MT; Pappalardi MB; Kasparec J; Tian X; McNulty KC; Rouse M; McDevitt P; Ho T; Crouthamel M; Hart TK; Concha NO; McHugh CF; Miller WH; Dhanak D; Tummino PJ; Carpenter CL; Johnson NW; Hann CL; Kruger RG
    Cancer Cell; 2015 Jul; 28(1):57-69. PubMed ID: 26175415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer.
    Kashyap V; Ahmad S; Nilsson EM; Helczynski L; Kenna S; Persson JL; Gudas LJ; Mongan NP
    Mol Oncol; 2013 Jun; 7(3):555-66. PubMed ID: 23384557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LSD1 regulates the balance between self-renewal and differentiation in human embryonic stem cells.
    Adamo A; Sesé B; Boue S; Castaño J; Paramonov I; Barrero MJ; Izpisua Belmonte JC
    Nat Cell Biol; 2011 Jun; 13(6):652-9. PubMed ID: 21602794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The deubiquitinase USP28 stabilizes LSD1 and confers stem-cell-like traits to breast cancer cells.
    Wu Y; Wang Y; Yang XH; Kang T; Zhao Y; Wang C; Evers BM; Zhou BP
    Cell Rep; 2013 Oct; 5(1):224-36. PubMed ID: 24075993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversible inhibition of lysine specific demethylase 1 is a novel anti-tumor strategy for poorly differentiated endometrial carcinoma.
    Theisen ER; Gajiwala S; Bearss J; Sorna V; Sharma S; Janat-Amsbury M
    BMC Cancer; 2014 Oct; 14():752. PubMed ID: 25300887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of histone demethylase, LSD2 (KDM1B), attenuates DNA methylation and increases sensitivity to DNMT inhibitor-induced apoptosis in breast cancer cells.
    Katz TA; Vasilatos SN; Harrington E; Oesterreich S; Davidson NE; Huang Y
    Breast Cancer Res Treat; 2014 Jul; 146(1):99-108. PubMed ID: 24924415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The histone LSD1 demethylase in stemness and cancer transcription programs.
    Amente S; Lania L; Majello B
    Biochim Biophys Acta; 2013 Oct; 1829(10):981-6. PubMed ID: 23684752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer.
    Kauffman EC; Robinson BD; Downes MJ; Powell LG; Lee MM; Scherr DS; Gudas LJ; Mongan NP
    Mol Carcinog; 2011 Dec; 50(12):931-44. PubMed ID: 21400613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of LSD1 inhibitors in lung cancer.
    Mohammad HP; Kruger RG
    Mol Cell Oncol; 2016 Mar; 3(2):e1117700. PubMed ID: 27308632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.